Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antiretroviral Therapy for Acute and Chronic HIV Infection
NCT00796263Phase 3Recruiting
- Sponsor
- SEARCH Research Foundation
- Start
- May 2009
- Primary completion
- Jun 2033
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of dolutegravir in human immunodeficiency virus infection (HIV), sponsored by SEARCH Research Foundation. Primary endpoints: HIV-related clinical events at 10 years, Immunologic parameters including CD4 count at 10 years and 3 more. Started May 2009; status: recruiting.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00796263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00796263.